Table 3.
Long-term demographic, clinical, laboratory, and procedural characteristics, medication, and scores of patients.
| Parameters | All patients (n : 478) | RSS = 0 (n : 130) | RSS < 7 (n : 185) | ≥7 (n : 163) | p value |
|---|---|---|---|---|---|
| Demographic parameters | |||||
| Age (year) | 62 ± 13 | 58 ± 12a | 61 ± 12a | 65 ± 13b | <0.001 |
| Male gender (n%) | 371 (77.6) | 101 (77.7) | 146 (78.9) | 124 (76.1) | 0.817 |
|
| |||||
| Clinical history | |||||
| HT (n%) | 285 (59.6) | 67 (51.5)a | 109 (58.9)a,b | 109 (66.9)b | 0.028 |
| DM (n%) | 216 (45.2) | 45 (34.6)a | 84 (45.4)a,b | 87 (53.4)b | 0.006 |
| HL (n%) | 282 (59) | 72 (55.4) | 114 (61.6) | 96 (58.9) | 0.541 |
| CAD (n%) | 104 (21.8) | 22 (16.9) | 37 (20) | 45 (27.6) | 0.067 |
| Smoking (n%) | 186 (38.9) | 55 (42.3) | 70 (37.8) | 61 (37.4) | 0.646 |
|
| |||||
| Laboratory parameters | |||||
| CreCl (ml/min) | 89.05 (72.6–100) | 92.32 (82–101)a | 91 (79–101.03)a | 83 (67–95.8)b | <0.001 |
| HbA1c | 6 (5.6–7) | 5.9 (5.5–6.8)a | 6 (5.6–6.8)a,b | 6.2 (5.7–7.4)b | 0.049 |
| Hb (g/dl) | 14.17 ± 4.92 | 14.05 ± 1.98 | 14.13 ± 1.91 | 14.31 ± 8 | 0.899 |
| WBC × 103 | 10.73 (8.43–13) | 10.04 (8–12.78) | 10.87 (8.25–12.73) | 10.9 (8.74–13.39) | 0.157 |
| PLT × 103 | 253.5 (208–304) | 262 (213–306) | 247 (207–292) | 247 (205–308) | 0.397 |
| CRP (mg/dl) | 1.8 (0.61–6) | 1.38 (0.5–3.58)a | 1.5 (0.57–4.93)a | 3.15 (0.78–11.1)b | <0.001 |
| Peak Trop-T (ng/ml) | 50000 (14.59–50000) | 34.37 (8.4–50000)a | 48.66 (13.3–50000)a | 50000 (31.9–50000)b | <0.001 |
| >50000 (n%) | 244 (51) | 50 (38.5)a | 91 (49.2)a | 103 (63.2)b | <0.001 |
| LVEF | 58 (50–60) | 60 (55–65)a | 60 (50–61)a | 52 (45–60)b | <0.001 |
| Grace Score | 105 (85–124) | 94.5 (80–109)a | 99 (81–121)a | 120 (103–138)b | <0.001 |
|
| |||||
| Angiographic characteristic | |||||
| One vessel (n%) | 149 (31.2) | 87 (66.9)a | 51 (27.6)b | 11 (6.7)c | <0.001 |
| Two vessels (n%) | 202 (42.3) | 35 (26.9)a | 105 (56.8)b | 62 (38)a | <0.001 |
| Three vessels (n%) | 149 (31.2) | 7 (5.4)a | 30 (16.2)b | 91 (55.8)c | <0.001 |
| IRA-LAD (n%) | 217 (45.4) | 65 (50)a | 95 (51.4)a | 57 (35)b | 0.004 |
| IRA-CX (n%) | 90 (18.8) | 25 (19.2) | 34 (18.4) | 31 (19) | 0.979 |
| IRA-RCA (n%) | 158 (33.1) | 35 (26.9)a | 53 (28.6)a | 70 (42.9)b | 0.004 |
| BMS (n%) | 119 (24.9) | 34 (26.2) | 44 (23.8) | 41 (25.2) | 0888 |
| DES (n%) | 41 (25.2) | 96 (73.8) | 141 (76.2) | 122 (74.8) | 0888 |
| Number of stents | 1 (1-1) | 1 (1-1)a | 1 (1-1)a,b | 1 (1-2)b | 0.021 |
| 1 (n%) | 380 (795) | 112 (86.2)a | 149 (80.5)a,b | 119 (73)b | 0.020 |
| ≥1 (n%) | 98 (20.5) | 18 (13.8)a | 36 (19.5)a,b | 44 (27)b | 0.020 |
| Stent length (mm) | 22 (16–30) | 19.5 (15–26)a | 24 (17–30)a | 24 (18–34)b | 0.002 |
| Stent diameter (mm) | 3 (2.75–3) | 3 (2.75–3.5) | 3 (2.75–3) | 3 (2.75–3) | 0.262 |
| SS | 16 (10–22.5) | 9.5 (7–15)a | 15 (10–20)b | 23.5 (18–29)c | <0.001 |
| RSS | 4 (0–8.5) | 0 (0-0)a | 3.5 (2–5)b | 12 (8–15.5)c | <0.001 |
|
| |||||
| Medication | |||||
| Beta-blocker (n%) | 448 (93.7) | 123 (94.6) | 174 (94.1) | 151 (92.6) | 0.765 |
| ASA (n%) | 476 (99.6) | 129 (99.2) | 185 (100) | 162 (99.4) | NA |
| Clopidogrel (n%) | 139 (29.1) | 26 (20)a | 61 (33)b | 52 (31.9)b | 0.028 |
| Prasugrel (n%) | 15 (3.1) | 2 (1.5) | 7 (3.8) | 6 (3.7) | 0.471 |
| Ticagrelor (n%) | 319 (66.7) | 101 (77.7)a | 115 (62.2)b | 103 (63.2)b | 0.008 |
| ACEI-ARB (n%) | 396 (82.8) | 105 (80.8) | 152 (82.2) | 139 (85.3) | 0.568 |
| Statin (n%) | 464 (97.1) | 126 (96.9) | 181 (97.8) | 157 (96.3) | 0.699 |
| MRA (n%) | 31 (6.5) | 6 (4.6) | 10 (5.4) | 15 (9.2) | 0.213 |
| Furosemide (n%) | 50 (10.5) | 9 (6.9)a | 12 (6.5)a | 29 (17.8)b | 0.001 |
| Follow-up (months) | 29 (18–35) | 28 (12–34) | 28 (14–38) | 30 (23–34) | 0.055 |
Data are presented as mean ± SD, median (0.250.75 percentiles), and n (%). ANOVA, Kruskal–Wallis test, and Pearson chi-square test were used and different letters show that there is a statistically significant difference. ACEI-ARB: angiotensin converting enzyme inhibitors-angiotensin receptor blockers, ASA: acetylsalicylic acid, BMS: bare metal stent, CAD: coronary artery disease, CreCl: creatinine clearance, CRP: C-reactive protein, CX: circumflex, DES: drug eluting stent, DM: diabetes mellitus, Hb: hemoglobin, HbA1C: hemoglobin A1C, HF: heart failure, HL: hyperlipidemia, HT: hypertension, IRA: infarct related artery, IV: intravenous, LAD: left anterior descending, LVEF: left ventricular ejection fraction, MRA: mineralocorticoid receptor antagonist, MI: myocardial infarction, NA: not applicable, PLT: platelet, RCA: right coronary artery, RSS: residual SYNTAX score, SS: SYNTAX score, Trop: troponin, and WBC: white blood cell.